Onco-Innovations Limited (NEO:ONCO)

Canada flag Canada · Delayed Price · Currency is CAD
1.300
-0.010 (-0.76%)
At close: Jan 8, 2026
21.50%
Market Cap73.03M
Revenue (ttm)154.67K
Net Income (ttm)-14.26M
Shares Out56.18M
EPS (ttm)-0.33
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume36,600
Average Volume24,659
Open1.270
Previous Close1.310
Day's Range1.250 - 1.300
52-Week Range0.900 - 2.800
Betan/a
RSI33.58
Earnings DateDec 12, 2025

About Onco-Innovations

Onco-Innovations Limited, a pre-clinical stage biotechnology company, develops drug candidates for cancer treatments. The company’s lead product candidate is ONC010, a novel inhibitor of the DNA repair enzyme a Polynucleotide Kinase 3′-Phosphatase (PNKP) in a nanoparticle formulation based on the drug delivery technology. Onco-Innovations Limited is headquartered in Calgary, Canada. [Read more]

Industry Biological Products, Except Diagnostic Substances
CEO Thomas O’Shaughnessy
Employees 1
Stock Exchange Cboe Canada
Ticker Symbol ONCO
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.